ANGIOTENSIN CONVERTING ENZYMES (ACE) INHIBITORS MARKET ANALYSIS

The global angiotensin converting enzymes (ACE) inhibitors market size is projected to reach US$ 11,831.7 million by 2030, from US$ 8,070.5 million in 2023, at a CAGR of 5.6% during the forecast period 2023-2030.

Angiotensin converting enzymes inhibitors are used for the treatment of various medical conditions such as hypertension, coronary artery disease, heart failure, diabetes, chronic kidney diseases, scleroderma, and migraines. Frequently prescribed angiotensin converting enzyme (ACE) inhibitors are benazepril, perindopril, trandolapril, captopril, enalaopril, lisinopril, and ramipril. ACE inhibitors are the first-choice drugs for the treatment of hypertension.

Global Angiotensin Converting Enzymes (ACE) Inhibitors Market- Regional Insights

• North America is the largest market for angiotensin converting enzymes (ACE) inhibitors, accounting for around 42.5% of the global market in 2022. This is due to the high prevalence of cardiovascular diseases, well-established healthcare infrastructure, and a growing aging population. The region is characterized by a strong presence of pharmaceutical companies, which has facilitated research and development of ACE inhibitors. Additionally, robust healthcare reimbursement systems and increased awareness of cardiovascular health contribute to the sustained market expansion in North America. Moreover, increasing organic strategies such as product approval are expected to drive market growth over the forecast period. For instance, on February 17, 2023, Travere Therapeutics, a biopharmaceutical company headquartered in California, U.S., announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to FILSPARI (sparsentan), to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.
• Europe is the second largest market for angiotensin converting enzymes (ACE) inhibitors, accounting for around 28.7% of the global market in 2022. In Europe, the global angiotensin converting enzymes (ACE) inhibitors market presents a mature landscape, with a significant emphasis on healthcare access and quality. The European market has benefited from strong healthcare systems and comprehensive insurance coverage, which ensures easy access to medications. However, the market faces challenges due to stringent regulatory requirements and price controls in several European countries, which can impact profit margins for pharmaceutical companies. Despite these challenges, the global angiotensin converting enzymes (ACE) inhibitors market in Europe continues to grow steadily, driven by a rising geriatric population and the increasing burden of cardiovascular diseases. For instance, in 2019, the European Society of Cardiology published a report on a contemporary analysis of cardiovascular disease (CVD) statistics, which states that there are more than 6 million new cases of cardiovascular diseases in Europe and more than 11 million in Europe as a whole every year. With almost 49 million people living with the disease in Europe (EU), the cost to the EU economies is high at US 230.3 (€210) million a year.
• Asia Pacific is the fastest growing market for angiotensin converting enzymes (ACE) inhibitors, accounting for around 20.0% of the global market in 2022. In the Asia Pacific region, the angiotensin converting enzymes (ACE) inhibitors market is marked by dynamic growth opportunities. This is attributed to factors such as the expanding middle-class population, urbanization, and a rising awareness of the importance of cardiovascular health. Additionally, governments in several Asia Pacific countries are taking initiatives to improve healthcare infrastructure and access to medications, further fueling market growth. The pharmaceutical industry in the region is actively pursuing research and development efforts in the field of cardiovascular medicines, contributing to innovation in ACE inhibitors. The Asia Pacific market for ACE inhibitors is poised for significant expansion in the coming years, making it a promising area for market players to invest and establish a strong presence. Moreover, increasing awareness for heart diseases is expected to augment the market growth over the forecast period. For instance, on June 26, 2023, patient organizations, allied health professionals, academia, corporate partners launched the Asia Pacific Cardiovascular Disease Alliance (APAC CVD Alliance), a multisectoral coalition committed to improving heart health and reducing the CVD burden across nine countries in Asia (Australia, China, India, Indonesia, Japan, Malaysia, South Korea, Thailand, Vietnam) to tackle heart disease in Asia with our strategic partners – the Asia Pacific Federation for Clinical Biochemistry and Laboratory Medicine (APFCB), Global Alliance for Patient Access (GAfPA), Global Heart Hub (GHH), and Universiti Teknologi MARA (UiTM) Faculty of Medicine in Malaysia – and corporate partners Amgen, Novartis, and Roche Diagnostics, the APAC CVD Alliance.

Figure 1. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market Share (%), By Region, 2023

To learn more about this report, request a free sample copy

Analyst’s View:

The Global Angiotensin Converting Enzymes (ACE) Inhibitors Market continues to exhibit robust growth owing to the escalating prevalence of cardiovascular diseases worldwide and the consequent rise in demand for effective treatments. The market is witnessing a steady expansion attributed to the increasing aging population, lifestyle changes leading to hypertension, and awareness regarding the benefits of ACE inhibitors in managing various cardiovascular conditions. Moreover, advancements in drug formulations, research, and development activities aimed at enhancing the efficacy and safety profiles of ACE inhibitors further propel market growth. The market's competitive landscape is characterized by key players focusing on strategic collaborations, product innovations, and geographical expansion to gain a competitive edge.

Global Angiotensin Converting Enzymes (ACE) Inhibitors Market- Drivers

• Rising prevalence of hypertension: The rising prevalence of hypertension serves as a significant driver for the angiotensin converting enzymes (ACE) inhibitors market. Hypertension, commonly known as high blood pressure, is a leading global health concern affecting millions of individuals across North America, Europe, and the Asia Pacific. This chronic condition is a key risk factor for cardiovascular diseases, including heart attacks and strokes, making it a major public health issue. For instance, on March 16, 2023, the World Health Organization (WHO) provided a data according to which an estimated 46% of people with hypertension are unaware that they have the illness, and 1.28 million people between the ages of 30 and 79 have hypertension globally.
• Growing Research and Development Activities: Growing research and development (R&D) activities in the field of pharmaceuticals serve as a key driver for the angiotensin converting enzymes (ACE) inhibitors market across North America, Europe, and the Asia Pacific. The pharmaceutical industry's continuous commitment to innovation and the development of new medications, including ACE inhibitors, is significantly influencing market dynamics in these regions. For instance, in March 2020, Elsevier, Dutch academic publishing company specializing in scientific, technical, and medical content published research data according to which patients with underlying health conditions such as hypertension, heart failure, and chronic kidney disease are at increased risk of severe coronavirus disease 2019 (COVID-19). Moreover, evidence shows that ACE inhibitors and angiotensin receptor blockers may improve prognosis in COVID-19 hypertensive patients.
• Increasing Awareness of Cardiovascular Health: Continuous research and development efforts have led to the introduction of new and improved angiotensin converting enzymes (ACE) inhibitors in the market. These advancements include the development of novel molecules and formulation technologies that enhance the efficacy and safety profiles of insulin sensitizing medications. For instance, on September 29, 2023, on World Heart Day, there is an initiative set to commence - the #UseHeart movement in collaboration with Iqniter, a prominent company specializing in health training devices. This collaboration aims to promote physical activity through its Counting Hearts Initiative, striving to reduce the prevalence of cardiovascular disease (CVD), which currently holds the unfortunate title of being the primary cause of fatalities.

Global Angiotensin Converting Enzymes (ACE) Inhibitors Market- Opportunities

• Innovative Drug Delivery Systems: Advancements in drug delivery systems, such as the development of more convenient and patient-friendly options like extended-release formulations or combination therapies, can enhance patient compliance and treatment effectiveness. Pharmaceutical companies can seize this opportunity to create differentiated products that offer improved patient outcomes and competitive advantages.
• Personalized medicine: The trend toward personalized medicine, driven by advancements in genomics and biomarker research, allows for the development of ACE inhibitors that are tailored to an individual's genetic and physiological profile. This approach can optimize treatment efficacy and minimize side effects, providing an opportunity for companies to lead in this evolving field.
• Combination therapies: Combining ACE inhibitors with other classes of medications, such as diuretics, beta-blockers, or calcium channel blockers, can provide a more comprehensive approach to managing hypertension and related cardiovascular conditions. Developing and marketing combination therapies can be a strategic opportunity for pharmaceutical companies to offer a broader spectrum of treatment options.

Global Angiotensin Converting Enzymes (ACE) Inhibitors Market- Trends

• Increasing Generic Competition: As many ACE inhibitors have reached or are approaching patent expiration, there is a growing presence of generic versions of these medications. This trend is driven by efforts to reduce healthcare costs and improve patient access to affordable treatment options. Pharmaceutical companies are adapting to this trend by focusing on the development of combination therapies, improved drug delivery systems, or seeking opportunities in emerging markets.
• Focus on Cardiovascular Health: The emphasis on cardiovascular health and prevention is driving the adoption of ACE inhibitors as part of early intervention strategies. Increased awareness and educational efforts encourage individuals to monitor their blood pressure and seek medical care, creating a trend of earlier diagnosis and treatment of hypertension and related conditions.
• Patient-Centered Care: There is a growing emphasis on patient-centered care in the management of hypertension and related conditions. Patients are taking a more active role in their healthcare decisions. This trend is influencing the development of ACE inhibitors with improved tolerability, reduced side effects, and more convenient dosing schedules to enhance patient satisfaction and adherence.
• Patient Education and Adherence Support: Patient education and adherence support programs are becoming more prevalent in the management of hypertension and cardiovascular conditions. These programs aim to improve patients understanding of the importance of medication adherence and lifestyle modifications. Pharmaceutical companies are developing educational materials and digital tools to aid in patient engagement and adherence.

Global Angiotensin Converting Enzymes (ACE) Inhibitors Market- Restraints

• Patent Expirations: Many ACE inhibitors have faced or will face patent expirations, allowing the entry of generic versions into the market. Generic competition can lead to price erosion and reduced profit margins for pharmaceutical companies, potentially impacting their willingness to invest in research and development.
• Side Effects and Safety Concerns: ACE inhibitors, like all medications, are associated with potential side effects. Cough, angioedema, and hyperkalemia are among the side effects that may limit the use of these drugs. Safety concerns can lead to reduced patient compliance and may necessitate discontinuation or switching to alternative treatments. Moreover, according to the data published by the Cleveland Clinic in October 2021, there are possible side effects and complication risks of ACE inhibitors. The most common side effects of almost all ACE inhibitors include dry cough, dizziness, headache, drowsiness, feeling fatigued, and weakness.
• Regulatory challenges and market access: Regulatory requirements and processes for the approval of angiotensin converting enzymes (ACE) inhibitors can be complex and time-consuming. Stringent regulatory guidelines, particularly in developed countries, may slow down the introduction of new angiotensin converting enzymes (ACE) inhibitors to the market. Market access barriers, such as reimbursement policies and formulary restrictions, can also limit patient access to certain angiotensin converting enzymes (ACE) inhibitors, impacting their adoption.
• Counterbalance: Patent expirations, while introducing generic competition, can lead to more affordable and accessible ACE inhibitors, potentially increasing patient adherence. Additionally, safety concerns are addressed through ongoing research and development efforts, improving the safety profile of ACE inhibitors. Stringent regulatory requirements, while demanding, ensure the availability of safe and effective treatments. Furthermore, competition from alternative therapies and emerging treatments fosters innovation, driving the development of novel ACE inhibitor formulations and personalized medicine approaches. These counterbalancing factors not only help the market adapt but also contribute to its resilience and the continued improvement of patient care.

Recent Developments

• On September 5, 2023, Pharmascience Canada, a Quebec-based pharmaceutical company, launched pms-PERINDOPRIL-INDAPAMIDE (perindopril erbumine or indapamide), a generic drug for adults for the initial treatment of mild to moderate essential hypertension (high blood pressure).
• In July 2022, Solco Healthcare, a fully owned subsidiary of Prinston Pharmaceutical, Inc., a generic pharmaceutical company that develops, manufactures and markets generic pharmaceuticals products and Zhejiang Huahai Pharmaceutical, a multinational enterprise, committed to providing high-quality medical and health products announced that Enalapril Maleate tablets, 2.5mg, 5mg, 10mg, and 20mg, have received U.S. Food and Drug Administration (FDA) which are AB-rated equivalent to Vasotec by Bausch Health.
• In February 2022, Camber Pharmaceuticals, a pharmaceutical company, announced the launch of Enalapril Maleate Oral Solution, a generic version of Epaned indicated for the treatment of hypertension, to lower blood pressure in adults and children older than one month.
• On February 16, 2021, Zent2U, the B2B business of Zentiva Group, a.s., a biopharmaceutical company, announced the successful completion of the development on ACE inhibitor Perindopril Arginine.

Acquisition, Agreement, Collaboration and partnerships

• In January 2020, AstraZeneca, one of the global biopharmaceutical companies, announced that it had signed an agreement with Atnahs Pharma (Atnahs), a specialty pharmaceutical business that acquires, markets, and develops mature branded medicines to sell the global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril), and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination).

Figure 2. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market Share (%), By Route of Administration, 2023

To learn more about this report, request a free sample copy

Top companies in Global Angiotensin Converting Enzymes (ACE) Inhibitors Market

• Novartis AG
• Pfizer Inc.
• Merck & Co.
• AstraZeneca
• Sanofi
• Boehringer Ingelheim
• GlaxoSmithKline
• Lupin Limited
• Torrent Pharmaceuticals Ltd.
• Reddy's Laboratories Ltd.
• Mylan
• Other Prominent Players

Definition: The global angiotensin converting enzymes (ACE) inhibitors refers to the pharmaceutical products or interventions that are designed to improve insulin sensitivity in individuals with conditions such as insulin resistance, type 2 diabetes, metabolic syndrome, and polycystic ovary syndrome (PCOS). Insulin sensitizers help body to utilize insulin more effectively, leading to improved glucose control and metabolic outcomes. The market encompasses various types of angiotensin converting enzymes (ACE) inhibitors, including medications, therapies, and related products, as well as the research, development, manufacturing, and distribution activities associated with them.